Skip to main content
. 2022 Jan 28;12:806963. doi: 10.3389/fonc.2022.806963

Figure 1.

Figure 1

Tumors with loss of SMAD4 display reduced lymphocyte infiltration independent of neoadjuvant chemotherapy status. (A) Excisional biopsies from 36 PDAC patients were sectioned and stained either with H&E or via immunohistochemistry for SMAD4, the pan-leukocyte antigen CD45, or T-cell marker CD3 and representative images shown for each from either chemotherapy naïve patients (N=18) or patients who had received neoadjuvant Gemcitabine-based chemotherapy (N=18). (B, C) The percent of patients from either the chemo-naïve or neoadjuvant Gemcitabine group that was either SMAD4-expressing (SMAD4+) or SMAD4-non-expressing (SMAD4-). (D, E) The number of CD45+ or CD3+ cells per 40X field was quantified by three blinded investigators, related to chemotherapy status, and displayed as an individual value plot. Using these values, the number of CD45 positive cells was next related to SMAD4 status in either (F) the chemo naïve group or (G) the neoadjuvant Gemcitabine group and displayed as an individual value plot. (H, I) The number of CD3+ T-cells were quantified as described and related to SMAD4 status in either the chemo-naïve group or the neoadjuvant Gemcitabine group and displayed as an individual value plot. (*p < 0.05).